GLAUKOS CORP

Drug pipeline (5)

Asset	Stage	Revenue	Trials	Status
EPIOXA HD/EPIOXA KIT	approved	—	0	—
IDOSE TR	approved	—	19	approved
MITOSOL	approved	—	4	approved
PHOTREXA VISCOUS IN DEXTRAN 20%	approved	—	0	—
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA	approved	—	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (29)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT05966493	phase2	recruiting	2023-08-17	2025-12-01	Glaukos Corporation	A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
NCT03868124	phase3	completed	2018-09-17	2022-06-10	Glaukos Corporation	Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
NCT00674661	phase3	completed	2007-12-01	2011-11-01	Glaukos Corporation	Corneal Collagen Cross-Linking for Ectasia (CXL)
NCT00647699	phase3	completed	2007-12-01	2011-04-01	Glaukos Corporation	Corneal Collagen Cross-linking for Progressive Keratoconus
NCT07629557	phase4	recruiting	2026-05-11	2027-09-01	Glaukos Corporation	Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

FDA applications (4)

Application

Approved

Type

Applicant

Products

NDA 219910

2025-10-17

NDA

GLAUKOS CORP

NDA 218010

2023-12-13

NDA

GLAUKOS CORP

NDA 203324

2016-04-15

NDA

GLAUKOS CORP

NDA 022572

2012-02-07

NDA

GLAUKOS CORP